-+ 0.00%
-+ 0.00%
-+ 0.00%

Bernstein Initiates Coverage On Summit Therapeutics with Underperform Rating, Announces Price Target of $7.7

Benzinga·05/22/2026 13:45:53
Listen to the news
Bernstein analyst Jeffrey Walch initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underperform rating and announces Price Target of $7.7.